Taken together, these findings establish HSP90, and particularly HSP90B1, as a prognostic biomarker and a functional DAMP in ccRCC, whose targeting may not only disrupt tumor cell homeostasis but also reprogram the tumor immune microenvironment toward enhanced immunogenicity [96]. This evidence concerns the gene HSP90B1 and nonpapillary renal cell carcinoma.